1-20 of 985
peripheral neuropathy
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Reducing the Burden of Chemoradiotherapy with the Combination of Brentuximab Vedotin and Rituximab with Reduced Toxicity Chemotherapy in Children, Adolescents and Young Adults with Newly Diagnosed Hodgkin Lymphoma

Free
Jessica C. Hochberg, MD, Jaclyn Basso, RN, MSN, PNP, Liana Klejmont, Pharm D, Lauren Harrison, RN, MSN, Allyson M. Flower, MD, Aliza Gardenswartz, MD, Qiuhu Shi, PhD, Perry Gerard, MD MBA, FACR, Humayan Islam, MD, Mitchell S Cairo, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 127.
https://doi.org/10.1182/blood-2019-128684
Published: 2019
Journal Articles

Peripheral Neuropathy in MGUS and Progression to Amyloid Light-Chain Amyloidosis: A Population-Based Study Including 15,351 MGUS Cases

Free
Sæmundur Rögnvaldsson, MD, Ingemar Turesson, MD PhD, Magnus Björkholm, MD PhD, Ola Landgren, MD PhD, Sigurður Yngvi Kristinsson, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5444.
https://doi.org/10.1182/blood-2019-131514
Published: 2019
Journal Articles

Response to Brentuximab Vedotin and Quality of Life in Patients with Relapsed/Refractory Hodgkin Lymphoma (RR HL) in the Real World Setting

Free
Tatyana Ionova, PhD Professor, Boris Afanasiev, MD PhD Professor, Maria Andrievskih, Alim Amdiev, Elena A. Baryakh, MD PhD, Viktor Chang, Gulnara Husainova, Vladimir Ivanov, Kamil D Kaplanov, MD, Oksana Kaverina, Tatiana Klitochenko, Vyacheslav Kurakin, Olga Larionova, Darya Lazareva, Kirill Lepik, Irina Lysenko, Nataliia Mikhailova, Raisa Minullina, Oleg Mironov, Elena Misyurina, Nikita Mochkin, Tatiana Nikitina, PhD, Iurii Osipov, Tatiana Petrova, Natalia Porfirieva, Oleg Rykavitcin, Rustem Safin, Tatiana Shelekhova, Dmitrij Sherstnev, Polina Simashova, Elena Smirnova, Natalia Trenina, Evgeniy V. Vasiliev, Mikhail Volkov, Elena Volodicheva, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5296.
https://doi.org/10.1182/blood-2019-121997
Published: 2019
Journal Articles

POLARGO: A Randomized Phase III Study Evaluating Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Who Had Received One or More Previous Therapies

Free
Andrew K McMillan, FRCP, Matthew J Matasar, MD, Juan-Manuel Sancho, MD PhD, Andreas Viardot, MD PhD, Juana Hernandez, MD, Thomas Perretti, MD MSc, Corinne Haioun, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5317.
https://doi.org/10.1182/blood-2019-123673
Published: 2019
Journal Articles

The Economic Burden of Short-Term Adverse Events Associated with the CHOP Chemotherapy Regimen in Patients with Lymphoproliferative Disorders in the United States: A Comprehensive Literature Review

Free
Crystal Watson, MS, Arie Barlev, PharmD, Jodie Worrall, Steve Duff, MS, Rachel Beckerman, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5826.
https://doi.org/10.1182/blood-2019-122611
Published: 2019
Journal Articles

Analysis of Falls in Older Adults with Multiple Myeloma Undergoing First-Line Therapy

Free
Kelly L. Schoenbeck, MD, Tanya M. Wildes, MD, Mark A. Fiala, BS
Journal: Blood
Blood (2019) 134 (Supplement_1): 5886.
https://doi.org/10.1182/blood-2019-129611
Published: 2019
Journal Articles

Evaluating the Utilization of All- T rans Retinoic Acid and Arsenic Trioxide during Consolidation Therapy for Patients Receiving Treatment for Acute Promyelocytic Leukemia

Free
Laura A Bowers, PharmD, Maho Hibino, PharmD, Rebecca Garcia Hunt, PharmD, Leslie Renee Ellis, MD, Rupali Bhave, MD, Dianna S. Howard, MD, Susan Lyerly, P.A.-C., Sarah Dralle, NP, Megan Manuel, NP, Timothy S. Pardee, MD PhD, Bayard L Powell, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3901.
https://doi.org/10.1182/blood-2019-131817
Published: 2019
Journal Articles

Randomized Comparison of Rituximab Versus Bortezomib Plus Cyclophosphamide and Dexamethasone in Newly Diagnosed Waldenstrom Macroglobulinemia Patients

Free
Shuhua Yi, MD, Wenjie Xiong, Yi Wang, Rui Lv, Li Zengjun, Wei Liu, Tingyu Wang, An Gang, MD, Shuhui Deng, MD, Yan Xu, MD, Weiwei Sui, Dehui Zou, MD, Lugui Qiu, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4003.
https://doi.org/10.1182/blood-2019-130133
Published: 2019
Journal Articles

Dose Reduction or Omission of Vinca Alkaloids during Initial Chemotherapy Treatment Does Not Impact Outcomes in Patients with Lymphoma

Free
Neelam Mistry, MD, Diana Abbott, PhD, Japera Walker Wilkison, MA, Ajay Major, MDMBA, Brad M. Haverkos, MDMPH,MS, Manali Kamdar, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4126.
https://doi.org/10.1182/blood-2019-129208
Published: 2019
Journal Articles

Rituximab Plus Gemcitabine and Oxaliplatin (R-GemOx) in Refractory/Relapsed (R/R) DLBCL. a Real Life Study in Patients Ineligible for Autologous Transplantation

Free
Clarisse Cazelles, Karim Belhadj, Helene Vellemans, Vincent Camus, Christiane Copie, MD PhD, Liana Veresezan, MD, Emmanuel Itti, MD PhD, Stephanie Becker, MD, Muriel verlinde Carvalho, Jehan Dupuis, MD, Fabien Le Bras, Francois Lemonnier, MD PhD, Louise Roulin, MD, Taoufik El Gnaoui, Fabrice Jardin, Nicolas Mounier, MD, Herve Tilly, MD PhD, Corinne Haioun, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4115.
https://doi.org/10.1182/blood-2019-124143
Published: 2019
Journal Articles

An Analysis from the WM UK Rory Morrison Registry: Waldenström's Macroglobulinaemia Patient Demographics, Disease Characteristics and Evolving Treatment Choices

Free
Oliver Tomkins, BMBS, MRCP, Joshua Bomsztyk, Helen McCarthy, MBBS, PhD, Jaimal Kothari, Dima El-Sharkawi, Charalampia Kyriakou, Guy Pratt, Ali Rismani, MBBS, Shirley D'Sa
Journal: Blood
Blood (2019) 134 (Supplement_1): 4016.
https://doi.org/10.1182/blood-2019-129212
Published: 2019
Journal Articles

Polatuzumab Vedotin Plus Bendamustine with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study

Free
Laurie H Sehn, MD, Matthew J Matasar, MD, Christopher R. Flowers, MD MS, Manali Kamdar, MD MD, Andrew K McMillan, FRCP, Mark Hertzberg, MD MBBS, PhD, Sarit Assouline, MD, Tae Min Kim, MD PhD, Won Seog Kim, MD PhD, Muhit Ozcan, MD, Brandon Croft, PharmD, Jamie Hirata, PharmD, Ji Cheng, PhD, Grace Ku, MD, Alex F. Herrera, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4081.
https://doi.org/10.1182/blood-2019-123449
Published: 2019
Journal Articles

Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Positive Peripheral T-Cell Lymphomas

Free
Alex F. Herrera, MD, Jasmine Zain, MD, Kerry J Savage, BSc, MD MSc, Tatyana A. Feldman, MD, Jonathan E Brammer, MD, Lu Chen, PhD, Leslie L. Popplewell, MD FRCPA, Lihua E Budde, MD PhD, Lacolle Peters, Yaira Kurtzman, Stephen J Forman, MD, Steven Rosen, MD, Larry W Kwak, MD PhD, Swaminathan P. Iyer, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4023.
https://doi.org/10.1182/blood-2019-123166
Published: 2019
Journal Articles

A Phase 2 Study of Retreatment with Brentuximab Vedotin in Patients with cHL, sALCL or Other CD30-Expressing PTCL

Free
Sairah Ahmed, MD, Julie Lisano, PharmD, Trevor Newhook, MS
Journal: Blood
Blood (2019) 134 (Supplement_1): 4054.
https://doi.org/10.1182/blood-2019-121523
Published: 2019
Journal Articles

Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study

Free
Nancy L. Bartlett, MD, David J. Straus, MD, Monika Dlugosz-Danecka, MD PhD, Sergey Alekseev, PhD, Arpad Illes, MD, Ewa Lech-Maranda, MD PhD, Tatyana A. Feldman, MD, Piotr Smolewski, MD PhD, Kerry J Savage, BSc, MD MSc, Jan Walewski, MD PhD, Radhakrishnan Ramchandren, MD, Pier Luigi Zinzani, MD PhD, Martin Hutchings, MD PhD, Joseph M. Connors, MD, John Radford, Javier Munoz, MD MS, FACP, Won-Seog Kim, MD PhD, Ranjana H Advani, MD, Stephen M Ansell, MD PhD, Anas Younes, MD, Andrea Gallamini, MD, Harry Miao, MD, Rachael Liu, PhD, Keenan Fenton, Andres Forero-Torres, MD, Marco Picardi, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4026.
https://doi.org/10.1182/blood-2019-124116
Published: 2019
Journal Articles

Outcome of Patients with Hodgkin Lymphoma Treated with Brentuximab Vedotin for Relapse after Autologous Stem Cell Transplant: A Retrospective Analysis of the LWP-EBMT

Free
Nikesh Dhiraj Chavda, MBBChir, Stephen Robinson, MBBS, PhD BSc, Ariane Boumendil, Irma Khvedelidze, Hervé Finel, Saad Akhtar, MD, M S Rauf, MD, Nadira Durakovic, MD, Radovan Vrhovac, MD PhD, Maurizio Musso, MD, Pauline Brice, Mutlu Arat, MD, Didier Blaise, MD PhD, Matthew P. Collin, MD PhD, Joanna Romejko-Jarosinska, MD PhD, Aspasia Stamatoullas, MD, Zubeyde Nur Ozkurt, MD, Tadeusz Robak, MD, Björn E Wahlin, MD PhD, Keith Wilson, FRCPath, MRCP, MBBS, Eleonora Alma, Rocco Pastano, Luca Castagna, MD, Ali Bazarbachi, MD PhD, Hervé Ghesquieres, MD PhD, Andrei Colita, MD PhD, Silvia Montoto, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4018.
https://doi.org/10.1182/blood-2019-131410
Published: 2019
Journal Articles

Lack of Benefit of Extended Vincristine and Dexamethasone Pulses during Maintenance Treatment of Childhood Acute Lymphoblastic Leukemia: A Multicenter Randomized Controlled Study of Chinese Children Cancer Group (CCCG)-ALL-2015

Free
Xiaofan Zhu, Shuhong Shen, MD PhD, Jiaoyang Cai, PhD, Shaoyan Hu, MD PhD, Ju Gao, PhD, Hui Zhang, MD PhD, Yongjun Fang, PhD, Xiuli Ju, Xiaowen Zhai, MD PhD, Xuedong Wu, MD PhD, Changda Liang, MD PhD, Xin Tian, PhD, Qun Hu, MD PhD, Ningling Wang, PhD, Runming Jin, MD, Hui Jiang, PhD, Lirong SUN, PhD, Minghua Yang, MD, Kaili Pan, PhD, Chi Kong Li, MBBS,MD, Jun J. Yang, PhD, Cheng Cheng, PhD, JingYan Tang, MD, Ching-Hon Pui, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2576.
https://doi.org/10.1182/blood-2019-128523
Published: 2019
Journal Articles

Current Selection Patterns, Toxicities and Outcomes of Pre-Transplant Salvage Treatment Regimens in Patients with Relapsed/Refractory Hodgkin Lymphoma: Results of a Multicenter Retrospective Analysis

Free
Jakub Svoboda, MD, Hatcher J. Ballard, BS, Steven M. Bair, MD, Rahul Banerjee, MD, Charalambos Andreadis, MD, Tatyana A. Feldman, MD, Elizabeth L. McCarthy, MSN, RN, Niloufer Khan, MD, Alison J. Moskowitz, MD, Victor M. Orellana-Noia, MD, Craig A. Portell, MD, Sarah J. Nagle, MD, Sunita Dwivedy Nasta, MD, Daniel J. Landsburg, MD, Stefan K. Barta, MD MRCP, MS, Elise A. Chong, MD, Stephen J Schuster, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2855.
https://doi.org/10.1182/blood-2019-123741
Published: 2019
Journal Articles

A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma

Free
Anita Kumar, MD, Carla Casulo, Ranjana H Advani, MD, Lihua E Budde, MD PhD, Paul M. Barr, MD, Connie Lee Batlevi, MD PhD, Philip Caron, MD PhD, Louis S. Constine, MD, Savita Dandapani, MD PhD, Esther Drill, PhD, Pamela Drullinsky, MD, Jonathan W. Friedberg, MD, Clare Grieve, BA, Audrey Hamilton, MD, Paul A. Hamlin, MD, Richard T Hoppe, MD, Steven M. Horwitz, MD, Matthew J Matasar, MD, Susan Jennifer McCall, NP, Alison J. Moskowitz, MD, Ariela Noy, MD, Maria Lia Palomba, MD, Heiko Schoder, MD, David J. Straus, MD, Shreya Vemuri, Joanna C Yang, MD MPH, Anas Younes, MD, Andrew D. Zelenetz, MD PhD, Joachim Yahalom, MD, Craig H. Moskowitz
Journal: Blood
Blood (2019) 134 (Supplement_1): 2834.
https://doi.org/10.1182/blood-2019-123150
Published: 2019
Journal Articles

Brentuximab Vedotin in Combination with Nivolumab, Doxorubucin, and Dacarbazine in Newly Diagnosed Patients with Advanced Stage Hodgkin Lymphoma

Free
Judah Friedman, MD, Hun Ju Lee, MD, Linda Ho, Ian W. Flinn, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2836.
https://doi.org/10.1182/blood-2019-122969
Published: 2019